At a glance
ClinicalIndex Comparison Record- ✓Histologically or cytologically confirmed unresectable stage IIIB non-small cell lung cancer
- ✓All detectable primary tumor and involved regional lymph nodes must be encompassed by radiotherapy fields
- ✓Measurable disease on 3-dimensional planning CT scan
- ✓ECOG 0-1 performance status
- ✕Small cell carcinoma or high-grade neuroendocrine carcinoma
- ✕Stage IV or recurrent disease
- ✕Distant metastases or supraclavicular lymph node involvement
- ✕Pleural effusions, pericardial effusions, or superior vena cava syndrome
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase I/II Dose Intensification Study Using Three Dimensional Conformal Radiation Therapy And Concurrent Chemotherapy For Patients With Inoperable, Non-Small Cell Lung Cancer
In Brief
A Phase 2 clinical trial evaluating carboplatin, paclitaxel, and 1 other intervention for Lung Cancer. Completed, enrolled 63 participants across 41 sites in 2 countries.
Detailed Summary
RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells. Drugs used in chemotherapy, such as paclitaxel and carboplatin, work in different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug and giving them with specialized radiation therapy may kill more tumor cells. PURPOSE: This phase I/II trial is studying the effectiveness of radiation therapy combined with paclitaxel and carboplatin in treating patients who have stage III non-small cell lung cancer.